200956-05-4Relevant academic research and scientific papers
Use of NK-1 receptor antagonists for treating major depressive disorders
-
, (2008/06/13)
The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor
Spirocyclic NK1 antagonists II: [4.5]-spiroethers
Williams, Brian J.,Cascieri, Margaret A.,Chicchi, Gary G.,Harrison, Timothy,Owens, Andrew P.,Owen, Simon N.,Rupniak, Nadia M.J.,Tattersall, David F.,Williams, Angela,Swain, Christopher J.
, p. 2719 - 2722 (2007/10/03)
A series of novel spiroether-based neurokinin-1 (NK1) antagonists is described. The effect of modifications to the spiroether ring and aromatic substituents are discussed, leading to the identification of compounds with high affinity and excellent CNS penetration.
Use of NK-1 receptor antagonists for treating stress disorders
-
, (2008/06/13)
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant the
USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING BIPOLAR DISORDERS
-
, (2008/06/13)
The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-
